



Prior Authorization Approval Criteria

Ranexa (ranolazine)

Generic name:	Ranolazine
Brand name:	Ranexa
Medication class:	Antianginal agent
FDA-approved uses:	Chronic, stable angina
Available dosage forms:	500 mg and 1000 mg tablets
Usual dose range:	Initiate at 500 mg twice a day and may increase to 1000 mg twice a day.
Duration of therapy:	Indefinite
Approximate monthly cost: <i>(based on AWP 2006)</i>	About \$205.80 per month for 500 mg b.i.d. \$411.60 per month for 1000 mg b.i.d.

Criteria for use *(bullet points below are all inclusive unless otherwise noted):*

- Patient remains symptomatic despite treatment with the maximum dose of at least 2 combined anti-anginal therapy such as; nitrates, beta-blockers, and calcium channel blockers.

Cautions:

- Increased risk of arrhythmias

Monitoring:

- Baseline and follow-up ECGs to evaluate Ranexa's effect of QT interval.

Contraindications:

- Pre-existing QT prolongation (including congenital long QT syndrome, uncorrected hypokalemia).
- Hepatic impairment (Child-Pugh Classes A, B, or C).
- Combined administration with other drugs that prolong QT interval (amiodarone, erythromycin, quinidine, sotalol, dofetilide, thioridazine, ziprasidone, etc.)
- Combined administration with drugs that inhibit CYP3A4 metabolism (azole antifungals, macrolide antibiotics, HIV protease inhibitors, diltiazem, verapamil, and grapefruit juice.)

Not approved if:

- The above criteria are not met.
- Patient has any contraindications to the use of Ranexa.

Special considerations:

- Patients have about 1 less angina episode per week.
- Ranolazine is less effective in women than in men.
- Doesn't lower blood pressure or heart rate like the others.
- Not for initial therapy because it can increase QT interval.
- If patient needs a calcium channel blocker (CCB) with ranolazine, amlodipine is recommended over other CCB's since it does not inhibit CYP3A4. ocular components of rosacea.

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 9/13/06